Numerous studies have demonstrated that brain
histamine plays a crucial role in learning and memory and
histamine H3 receptor inverse agonists (H3R inverse agonists) have been proposed to treat
cognitive disorders.
Pitolisant (
BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}
piperidine, hydrochloride) was the first H3R inverse agonist that has been tested in human trials and is well tolerated. The present study investigated whether
Pitolisant (0.625-20mg/kg, i.p.) improves consolidation and reconsolidation processes in the fear conditioning task in female C57BL/6J mice. We also tested whether
Pitolisant reverses
memory deficits induced by the non-competitive
N-methyl-d-aspartate (
NMDA) antagonist
dizocilpine (MK-801). Our results indicate that post-training systemic
injections of
Pitolisant facilitated consolidation of contextual fear memory and reversed
amnesia induced by an i.p. injection of 0.12 mg/kg
dizocilpine. In addition, none of the doses of
Pitolisant we have tested after reactivation (reexposure to the context in which training took place 48 h earlier) affected reconsolidation, whereas
dizocilpine disrupted it. However,
Pitolisant was able to reverse the deficit in reconsolidation induced by 0.12 mg/kg
dizocilpine. The present results are the first demonstration that
Pitolisant is effective in improving consolidation processes in the fear condition task and add further evidence to its potential for treating
cognitive disorders.